Soligenix to present key findings on HyBryte™ and SGX302 at USCLC workshop and AAD annual meeting

Soligenix, Inc announced  its lead investigators for the cutaneous T-cell lymphoma (CTCL) and psoriasis programs are presenting findings from recent supportive trials with HyBryte™ (synthetic hypericin) in the treatment of CTCL and SGX302 (synthetic hypericin) in the treatment of mild-to-moderate psoriasis. The presentations will occur at the United States Cutaneous Lymphoma Consortium (USCLC) Workshop (March 6, 2025) and the American Academy of Dermatology (AAD) Annual Meeting (March 7-11, 2025). Ellen Kim, MD, Director, Penn Cutaneous Lymphoma Program, Vice Chair of Clinical Operations, Dermatology Department, and Professor of Dermatology at the Hospital of the University of Pennsylvania, and who was the Principal Investigator for the first Phase 3 FLASH (Fluorescent Light Activated Synthetic Hypericin) study, will present a poster at the USCLC detailing recent results from an ongoing investigator-initiated study using HyBryte™ as a long-term treatment of CTCL. Neal Bhatia, MD, FAAD, Director of Clinical Dermatology at Therapeutics Clinical Research and Principal Investigator of Study HPN-PSR-01, and who participated in the FLASH study, will present at the AAD and discuss general considerations on the use of topical and photodynamic therapy, including synthetic hypericin.

Presentations:

Conference: USCLC Workshop “Cutaneous Lymphomas in Special Populations” March 6, Orlando, Florida. The official conference program can be found here.
Presentation Title: Topical hypericin ointment photodynamic therapy for early stage mycosis fungoides/CTCL – a Phase 2 real world investigator-initiated study presented by Dr. Ellen Kim, Director, Penn Cutaneous Lymphoma Program, Vice Chair of Clinical Operations, Dermatology Department, and Professor of Dermatology at the Hospital of the University of Pennsylvania.

Conference: AAD Annual Meeting, March 7-11, Orlando, Florida
Presentation Title: What’s new this year in Topical therapy? presented by Dr. Neal Bhatia, Director of Clinical Dermatology at Therapeutics Clinical Research and chief medical editor at Practical Dermatology. The official conference program can be found here.

These presentations incorporate the Company’s findings in recent supportive studies which have demonstrated the utility of longer treatment times (Study RW-HPN-MF-01; investigator-initiated study), the lack of significant systemic exposure to hypericin after topical application (Study HPN-CTCL-02) and its relative efficacy and tolerability compared to Valchlor^® (Study HPN-CTCL-04).